Share-based Payment Arrangement, Expense of Terns Pharmaceuticals, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Terns Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Terns Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,341,000, a 20% decline year-over-year.
  • Terns Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $13,067,000, a 18% decline year-over-year.
  • Terns Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $15,627,000, a 39% decline from 2023.
  • Terns Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25,536,000, a 137% increase from 2022.
  • Terns Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,768,000, a 32% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Terns Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $13,067,000 $3,341,000 -$817,000 -20% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $13,884,000 $3,028,000 -$1,392,000 -31% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $15,276,000 $3,677,000 -$351,000 -8.7% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $15,627,000 $3,021,000 -$261,000 -8% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $15,888,000 $4,158,000 -$9,925,000 -70% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $25,813,000 $4,420,000 +$187,000 +4.4% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $25,626,000 $4,028,000 +$90,000 +2.3% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $25,536,000 $3,282,000 +$595,000 +22% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $24,941,000 $14,083,000 +$11,397,000 +424% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $13,544,000 $4,233,000 +$1,582,000 +60% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $11,962,000 $3,938,000 +$1,194,000 +44% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q4 2022 $10,768,000 $2,687,000 +$137,000 +5.4% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $10,631,000 $2,686,000 +$831,000 +45% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $9,800,000 $2,651,000 +$742,000 +39% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $9,058,000 $2,744,000 +$912,000 +50% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $8,146,000 $2,550,000 +$1,764,000 +224% 01 Oct 2021 31 Dec 2021 10-K 27 Mar 2023 2022 FY
Q3 2021 $6,382,000 $1,855,000 +$1,342,000 +262% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $5,040,000 $1,909,000 +$1,719,000 +905% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $3,321,000 $1,832,000 +$1,630,000 +807% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $1,691,000 $786,000 01 Oct 2020 31 Dec 2020 10-K 07 Mar 2022 2021 FY
Q3 2020 $513,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $190,000 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $202,000 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1

Terns Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $15,627,000 -$9,909,000 -39% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $25,536,000 +$14,768,000 +137% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $10,768,000 +$2,622,000 +32% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $8,146,000 +$6,455,000 +382% 01 Jan 2021 31 Dec 2021 10-K 27 Mar 2023 2022 FY
2020 $1,691,000 01 Jan 2020 31 Dec 2020 10-K 07 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.